請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/29542
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 陳建仁(Chein-Jen Chen) | |
dc.contributor.author | Yu-Ling Chen | en |
dc.contributor.author | 陳毓翎 | zh_TW |
dc.date.accessioned | 2021-06-13T01:09:54Z | - |
dc.date.available | 2007-08-08 | |
dc.date.copyright | 2007-08-08 | |
dc.date.issued | 2007 | |
dc.date.submitted | 2007-07-23 | |
dc.identifier.citation | REFERENCES
1. Lok AS. Natural history and control of perinatally acquired hepatitis B virus infection. Digestive Disease 1992; 10(1):46-52. 2. Fattovich G. Progression of hepatitis B and C to hepatocellular carcinoma in Western countries. Hepato-Gastroenterology 1998;45 Suppl 3:1206-1213. 3. Beasley RP. Hepatitis B virus—the major etiology of hepatocellular carcinoma. Cancer 1988; 61(10):1942–1956. 4. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2001; 34(6):1225–1241. 5. Hsu YS, Chien RN, Yeh CT et al. Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology 2002; 35(6):1522–1527. 6. Fattovich G, Brollo L, Guistina G et al. Natural history and prognostic factors for chronic hepatitis type B. Gut. 1991; 32(3):294–298. 7. Huo T, Wu JC, Hwang SJ et al. Factors predictive of liver cirrhosis in patients with chronic hepatitis B: a multivariate analysis in a longitudinal study. European Journal of Gastroenterology & Hepatology. 2000; 12(6):687–693. 8. Lin SM, Sheen IS, Chien RN et al. Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection. Hepatology 1999; 29(3):971–975. 9. Liaw YF, Tai DI, Chu CM et al. The development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Hepatology 1988; 8(3):493–496. 10. Yu MW, Hsu FC, Sheen IS et al. Prospective study of hepatocellular carcinoma and liver cirrhosis in asymptomatic chronic hepatitis B virus carriers. American Journal of Epidemiology 1997; 145(11):1039–1047. 11. Mahoney FJ. Update on diagnosis, management, and prevention of hepatitis B virus infection. Clinical Microbiology Review1999; 12(2):351–366. 12. Beasley R, Hwang L-Y. Overview of the epidemiology of hepatocellular carcinoma. Baltimore: 1991. 13. Hsieh CC, Tzonou A, Zavitsanos X et al. Age at first establishment of chronic hepatitis B virus infection and hepatocellular carcinoma risk. A birth order study. American Journal of Epidemiology 1992; 136(9):1115–1121. 14. Fattovich G, Pantalena M, Zagni I et al. Effect of hepatitis B and C virus infections on the natural history of compensated cirrhosis: a cohort study of 297 patients. American Journal of Gastroenterology 2002; 97(11):2886–2895. 15. de Jongh FE, Janssen HL, de Man RA et al. Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver. Gastroenterology 1992; 103(5):1630–1635. 16. Tamura I, Kurimura O, Koda T et al. Risk of liver cirrhosis and hepatocellular carcinoma in subjects with hepatitis B and delta virus infection: a study from Kure, Japan. Journal of Gastroenterology & Hepatology 1993; 8(5):433–436. 17. Realdi G, Fattovich G, Hadziyannis S et al. Survival and prognostic factors in 366 patients with compensated cirrhosis type B: a multicenter study. Journal of Hepatology 1994; 21(4):656–666. 18. Iloeje UH, HI Yang, Jun Su et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006; 130(3):678-686. 19. Norder H, Hammas B, Lofdahl S et al. Comparison of the amino acid sequences of nine different serotypes of hepatitis B surface antigen and genomic classification of the corresponding hepatitis B virus strains. Journal of General Virology 1992; 73(5):1201-1208. 20. Arauz-Ruiz P, Norder H, Robertson BH et al. Genotype H: a new Amerindian genotype of hepatitis B virus revealed in Central America. Journal of General Virology 2002; 83(8):2059-2073. 21. Kao JH, Chen PJ, Lai MY et al. Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B. Gastroenterology 2000; 118(3):554-559. 22. Kao JH, Chen PJ, Lai MY, Chen DS. Clinical and virological aspects of blood donors infected with hepatitis B virus genotypes B and C. Journal of Clinical Microbiology 2002; 40(1):22-25. 23. Orito E, Ichida T, Sakugawa H et al. Geographic distribution of hepatitis B virus (HBV) genotype in patients with chronic HBV infection in Japan. Hepatology 2001; 34(3):590-594. 24. Chu CJ, Hussain M, Lok AS. Hepatitis B virus genotype B is associated with earlier HBeAg seroconversion compared with hepatitis B virus genotype C. Gastroenterology 2002; 122(7):1756-1762. 25. Sumi H, Yokosuka O, Seki N et al. Influence of hepatitis B virus genotypes on the progression of chronic type B liver disease. Hepatology 2003; 37(1):19-26. 26. Kao JH, Chen PJ, Lai MY et al. Genotypes and clinical phenotypes of hepatitis B virus in patients with chronic hepatitis B virus infection. Journal of Clinical Microbiology 2002; 40(4):1207-1209. 27. Kao JH, Wu NH, Chen PJ et al. Hepatitis B genotypes and the response to interferon therapy. Journal of Hepatology 2000; 33(6):998-1002. 28. Yu MW, Yeh SH, Chen PJ et al. Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men. Journal of the National Cancer Institute 2005; 97(4):265-272. 29. Scaglioni PP, Melegari M, Wands JR. Posttranscriptional regulation of hepatitis B virus replication by the precore protein. Journal of Virology 1997; 71(1):345–353 30. Hadziyannis S. Hepatitis B e antigen negative chronic hepatitis B: from clinical recognition to pathogenesis and treatment. Viral Hepatitis Review 1995;1:7–36 31. Hunt CM, McGill JM, Allen MI et al. Clinical relevance of hepatitis B viral mutations. Hepatology 2000; 31(5):1037–1044 32. Gunther S, Fischer L, Pult I et al. Naturally occurring variants of hepatitis B virus. Advances in Virus Research 1999; 52:25-137. 33. Bartholomeusz A, Locarnini S. Hepatitis B virus mutants and fulminant hepatitis B: fitness plus phenotype. Hepatology 2001; 34(2):432-435. 34. Carman WF, Jacyna MR, Hadziyannis S et al. Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection. Lancet 1989; 334(8663):588-591. 35. Omata M, Ehata T, Yokosuka O et al. Mutations in the precore region of hepatitis B virus DNA in patients with fulminant and severe hepatitis. New England Journal of Medicine 1991; 324(24):1699-1704. 36. Liang TJ, Hasegawa K, Rimon N et al. A hepatitis B virus mutant associated with an epidemic of fulminant hepatitis. New England Journal of Medicine 1991; 324(24):1705-1709. 37. Brunetto MR, Giarin MM, Oliveri F et al. Wild-type and e antigen-minus hepatitis B viruses and course of chronic hepatitis. Proceedings of the National Academy of Sciences of the United States of America 1991; 88(10):4186-4190. 38. Okamoto H, Yotsumoto S, Akahane Y et al. Hepatitis B viruses with precore region defects prevail in persistently infected hosts along with seroconversion to the antibody against e antigen. Journal of Virology 1990; 64(3):1298–1303. 39. Okamoto H, Tsudsa F, Akahane Y et al. Hepatitis B virus with mutations in the core promoter for an e antigen-negative phenotype in carriers with antibody to e antigen. Journal of Virology 1994; 68(12):8102-8110. 40. Gu¨nther S, Piwon N, Will H. Wild-type levels of pregenomic RNA and replication but reduced pre-C RNA and e-antigen synthesis of hepatitis B virus with C(1653)3T, A(1762) 3T and G (1764) 3 A mutations in the core promoter. Journal of General Virology. 1998; 79(2):375–380. 41. Rokuhara A, Kiyosawa K. Hepatitis B virus: mutations in the precore/basal core promoter and viral replication. Journal of Gastroenterology 2002; 37(4):318-320. 42. Kramvis A, Kew MC. Relationship of genotypes of hepatitis B virus to mutations, disease progression and response to antiviral therapy. Journal of Viral Hepatitis 2005; 12(5):456-464. 43. Milich DR, Jones JE, Hughes JL et al. Is a function of the secreted hepatitis B e antigen to induce immunologic tolerance in utero? Proceedings of the National Academy of Sciences of theUnited States of America 1990; 87(17):6599-6603. 44. Kao JH, Chen PJ, Lai MY et al. Basal core promoter mutations of hepatitis B virus increase the risk of hepatocellular carcinoma in hepatitis B carriers. Gastroenterology 2003; 124(2):327-334. 45. Lin CL, Liao LY, Wang CS et al. Basal core-promoter mutant of hepatitis B virus and progression of liver disease in hepatitis B e antigen-negative chronic hepatitis B. Liver International 2005; 25(3):564-570. 46. Liu CJ, Chen BF, Chen PJ et al. Role of hepatitis B viral load and basal core promoter mutation in hepatocellular carcinoma in hepatitis B carriers. Journal of Infectious Disease 2006; 193(9):1258-1265. 47. Yuen MF, Tanaka Y, Mizokami M et al. Role of hepatitis B virus genotypes Ba and C, core promoter and precore mutations of hepatocellular carcinoma: a case control study. Carcinogenesis 2004; 25(9):1593-1598. 48. Lok AS, Heathcote EJ, Hoofnagle JH. Management of hepatitis B: 2000--summary of a workshop. Gastroenterology 2001; 120(7):1828-1853. 49. Yeh SH, Tsai CY, Kao JH et al. Quantification and genotyping of hepatitis B virus in a single reaction by real-time PCR and melting curve analysis. Journal of Hepatology 2004; 41(4):659-666. 50. Lin DY, Sheen IS, Chiu CT et al. Ultrasonographic changes of early liver cirrhosis in chronic hepatitis B: a longitudinal study. Journal of Clinical Ultrasound 1993; 21(5):303–308. 51. Nelson W. Theory and applications of hazard plotting for censored failure data. Technometrics 1972;14(4): 945–965. 52. Breslow N, Crowley J. A large sample study of the life table and product limit estimates under random censorship. Annals of Statistics 1974; 2(3):437–453. 53. Aalen O. Nonparametric inference for a family of counting processes. Annals of Statistics 1978; 6(4):701–726. 54. Chu CM, Liaw YF. Genotype C hepatitis B virus infection is associated with a higher risk of reactivation of hepatitis B and progression to cirrhosis than genotype B: a longitudinal study of hepatitis B e antigen-positive patients with normal aminotransferase levels at baseline. Journal of Hepatology 2005; 43(3): 411-417. 55. Nakayoshi T, Maeshiro T, Nakayoshi T et al. Difference in prognosis between patients infected with hepatitis B virus with genotype B and those with genotype C in the Okinawa islands: a prospective study. Journal of Medical Virology 2003; 70(3):350-354. 56. Yu MW, Yang YC, Yang SY et al. Androgen receptor exon 1 CAG repeat length and risk of hepatocellular carcinoma in women. Hepatology 2002; 36(1):156-163. 57. Yeh SH, Chang CF, Shau WY et al. Dominance of functional androgen receptor allele with longer CAG repeat in hepatitis B virus-related female hepatocarcinogenesis. Cancer Research 2002; 62(15):4346-4351. 58. Parekh S, Zoulim F, Ahn SH et al. Genome replication, virion secretion, and e antigen expression of naturally occurring hepatitis B virus core promoter mutants. Journal of Virology 2003; 77(12): 6601–6612. 59. Orito E, Mizokami M, Sakugawa H et al. A case-control study for clinical and molecular biological differences between hepatitis B viruses of genotypes B and C. Japan HBV Genotype Research Group. Hepatology 2001; 33(1):218-223. 60. Lindh M, Hannoun C, Dhillon AP et al. Core promoter mutations and genotypes in relation to viral replication and liver damage in East Asian hepatitis B virus carriers. Journal of Infectious Diseases 1999; 179(4):775–782. 61. Yu MW, Cheng SW, Lin MW et al. Androgen-receptor gene CAG repeats, plasma testosterone levels, and risk of hepatitis B-related hepatocellular carcinoma. Journal of National Cancer Institute 2000; 92(24):2023-2028. 62. Yu MW, Yang YC, Yang SY et al. Hormonal markers and hepatitis B virus-related hepatocellular carcinoma risk: a nested case-control study among men. Journal of National Cancer Institute 2001; 93(21):1644-1651. 63. Chan HL, Tsang SW, Liew CT et al. Viral genotype and hepatitis B virus DNA levels are correlated with histological liver damage in HBeAg-negative chronic hepatitis B virus infection. American Journal of Gastroenterology 2002; 97(2):406-412. 64. Sung JJ, Chan HL, Wong ML et al. Relationship of clinical and virological factors with hepatitis activity in hepatitis B e antigen-negative chronic hepatitis B virus-infected patients. Journal of Viral Hepatitis 2002; 9(3):229-234. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/29542 | - |
dc.description.abstract | 目的 目前研究普遍認為,在預測肝硬化、肝細胞癌與B型肝炎相關肝臟疾病之預後,血中B 型肝炎病毒量為一強而有力的預測因子。然而在與病毒本身相關的其他因子中,病毒基因型及和e 抗原合成量相關之病毒突變株,在相關肝臟疾病病程中所扮演的角色仍有待釐清。本研究乃以前瞻性世代研究法來探討B 型肝炎病毒B、C基因型、precore stop codon G1896A 突變和basal core promoter A1762T/G1764A 雙突變對於發生肝硬化的影響。
方法 研究世代建立於1991至1992年間,參與對象為台灣七個鄉鎮市區30至65歲的居民,而本研究係針對當中2,692名B 型肝炎表面抗原陽性、C 型肝炎抗體陰性且未接受過抗病毒藥物治療的世代成員進行分析。個案在納入研究世代之初的血清進行B 型肝炎病毒量和病毒基因型之檢測,而病毒量達104 copies/mL 以上者再另外檢測血清中是否存在B型肝炎病毒 G1896A 和A1762T/G1764A突變株。肝硬化診斷工具為腹部超音波,並排除進入研究半年內之肝硬化新發個案。 結果 截至2004年6月30日止,共追蹤了30,939人年,個案平均追蹤時間為11.5年,追蹤期間有305個肝硬化新發個案。個案肝硬化的發生率(每十萬人年)在感染B基因型與C基因型病毒者中分別為768.2 和 1,585.3;帶有precore野生型及突變株G1896A個案的發生率分別為1,985.7 和 881.0;帶有BCP野生型及突變株 A1762T/G1764A 個案的發生率則為912.6 和 2,210.2。在調整了性別、年齡、抽煙、喝酒、e抗原與ALT狀態和B型肝炎病毒量後,感染基因型C者相對於感染基因型B者發生肝硬化的風險比(hazard ratio)為1.7 (95%信賴區間:1.4-2.2);帶有precore G1896A突變株相對於其野生型的風險比為0.6(95%信賴區間:0.4-0.9);而帶有BCP A1762T/G1764A突變株相對於其野生型的風險比為1.9 (95%信賴區間:1.4-2.5)。 結論 B 型肝炎病毒C 基因型以及BCP A1762T/G1764A突變株是肝硬化的危險因子,而precore G1896A突變株則對肝硬化的發生具有保護作用。 | zh_TW |
dc.description.abstract | Objective
Although HBV DNA level has been shown to be an independent risk predictor for liver cirrhosis, the roles of HBV genotype and mutants in the progression of liver cirrhosis remain unclear. The aim of this study was to investigate the risk of cirrhosis associated with genotype, precore stop codon G1896A mutation and A1762T/G1764A double mutation in the basal core promoter (BCP) of hepatitis B virus (HBV). Methods A cohort of 2,692 untreated participants (aged 30–65), who were HBsAg(+) and anti-HCV-seronegative, was enrolled from seven townships in Taiwan between 1991 and 1992. Serum samples at cohort entry were tested for HBV viral load and genotype. A sub-cohort of 1,477 participants with HBV DNA levels ≥ 104 copies/mL was further tested for HBV mutants of G1896A and A1762T/G1764A. Newly developed liver cirrhosis cases were diagnosed by ultrasonography. Results Up to June 30, 2004, 305 newly diagnosed cirrhosis cases had occurred during 30,939 person-years of follow-up, with a mean follow-up time of 11.5 years. The incidence rates per 100,000 person-years for participants infected with HBV genotype B and C were 768.2 and 1,585.3, respectively. For participants infected with wild and mutant type HBV precore stop codon 1896, rates were 1,985.7 and 881.0, respectively; and for participants infected with wild and typical mutant type HBV BCP 1762/1764, rates were 912.6 and 2,210.2, respectively. After adjustment for gender, age, cigarette smoking, alcohol consumption, HBeAg status, ALT level, and HBV viral load, the hazard ratio (95% confidence interval) of liver cirrhosis was 1.7 (1.4–2.2) for genotype C compared with genotype B, 0.6 (0.4–0.9) for G1896A mutant compared with wild type, and 1.9 (1.4–2.5) for A1762T/G1764A mutant compared with wild type. Conclusion HBV genotype C and A1762T/G1764A mutants were risk factors for liver cirrhosis, while the emergence of G1896A mutant seemed to have a protective effect on the progression of liver cirrhosis. | en |
dc.description.provenance | Made available in DSpace on 2021-06-13T01:09:54Z (GMT). No. of bitstreams: 1 ntu-96-R94842015-1.pdf: 332118 bytes, checksum: 43e2a5cc28fb5bb61ecc97ff884acd98 (MD5) Previous issue date: 2007 | en |
dc.description.tableofcontents | TABLE OF CONTANTS
中文摘要..................................................i ABSTRACT................................................iii LIST OF TABLES...........................................vi LIST OF FIGURES.........................................vii INTRODUCTION..............................................1 Liver Cirrhosis..........................................1 HBV Genotype.............................................2 HBV Mutants..............................................3 Precore Mutation.........................................4 Basal Core Promoter Mutation...........................5 METHODS...................................................7 Study Population.........................................7 Interview and Blood Collection...........................8 Laboratory Analysis......................................8 Ascertainment of Cirrhosis..............................10 Data Analysis...........................................11 RESULTS..................................................13 Characteristics of the Study Participants...............13 Prevalence of HBV Genotype and Mutants by Risk Factors..13 Incidence Rates and Cumulative Incidence................14 Multivariable –adjusted HRs............................16 Subgroups Analysis......................................16 Combined Effects of Precore and BCP Mutants.............17 DISCUSSION...............................................19 REFERENCES...............................................25 TABLES...................................................31 FIGURES..................................................46 | |
dc.language.iso | en | |
dc.title | 感染不同B型肝炎病毒基因型及突變株對罹患肝硬化危險性之相關性研究 | zh_TW |
dc.title | Risk of Liver Cirrhosis Associated with Genotypes and Mutants of HBV | en |
dc.type | Thesis | |
dc.date.schoolyear | 95-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 楊懷壹,于明暉,陳培哲,李文宗 | |
dc.subject.keyword | B 型肝炎病毒,肝硬化,B型肝炎病毒基因型,B型肝炎病毒突變株,Precore,Basal Core Promoter, | zh_TW |
dc.subject.keyword | Hepatitis B Virus,Liver Cirrhosis,HBV Genotype,HBV Mutants,Precore,Basal Core Promoter, | en |
dc.relation.page | 49 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2007-07-23 | |
dc.contributor.author-college | 公共衛生學院 | zh_TW |
dc.contributor.author-dept | 流行病學研究所 | zh_TW |
顯示於系所單位: | 流行病學與預防醫學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-96-1.pdf 目前未授權公開取用 | 324.33 kB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。